Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Swaminathan R Natarajan

James B Doherty

Luping Liu

Meng-Hsin Chen

Robert M Tynebor

John E Stelmach

Meng Hsin Chen

Dong-Ming Shen

Kathleen M Rupprecht

Peter J Sinclair

Jianming Bao

Soumya P Sahoo

Shouwu Miao

Julianne A Hunt

Joung L Goulet

Zhen Li

Florida Kallashi

David D Wisnoski

Xingfang Hong

Rowena D Ruzck

Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: (I) are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation. 

P38 kinase inhibiting agents

This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

Ophthalmic compositions for treating ocular hypertension

This invention relates to potent potassium channel blocker compounds of structural Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

This invention relates to potent potassium channel blocker compounds of Formula (I) or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans, or a pharmaceutically acceptable salt, in vivo hydrolysable ester, enantiomer, diastereomer or mixture thereof: formula (II) represents Caryl or Cheterocyclyl, said aryl or heterocyclyl optionally substituted with 1-3 groups selected from R; Z represents (CH)PO(OR)(OR*). 

Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: (I) are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation 

(Halo-benzo carbonyl)heterobi cyclic p38 linase inhibiting agents

This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

(Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents

Growing community of inventors

Scotch Plains, NJ, United States of America

Swaminathan R Natarajan